Investigation of Novel Therapies for Hyperammonemia by de Angelis, Angela
Open Research Online
The Open University’s repository of research publications
and other research outputs
Investigation of Novel Therapies for Hyperammonemia
Thesis
How to cite:
de Angelis, Angela (2019). Investigation of Novel Therapies for Hyperammonemia. PhD thesis. The Open University.
For guidance on citations see FAQs.
c© 2019 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
ANGELA DE ANGELIS 
 
 
Investigation of novel therapies for 
hyperammonemia. 
 
 
Ph.D. Thesis 
 
 
The Open University 
Affiliated Research Centre: 
Telethon institute of Genetics and Medicine (TIGEM) 
 
 
Director of Studies: Prof. Nicola Brunetti-Pierri 
 
 
 
Thesis submitted in accordance with the requirements of 
The Open University for the degree “Doctor of Philosophy” 
September 2019 
1 
 
Table of Contents 
Abstract .............................................................................................................................................................. 2 
List of abbreviations ........................................................................................................................................... 4 
Introduction ........................................................................................................................................................ 6 
Ammonia metabolism ..................................................................................................................................... 6 
Hyperammonemia: pathogenesis and treatments .......................................................................................... 9 
O-GlcNAcylation: mechanisms and functions ............................................................................................ 11 
Aims of the thesis ........................................................................................................................................... 14 
Results (Aim 1) ................................................................................................................................................ 15 
Hepatic GS  overexpression for therapy of hyperammonemia ..................................................................... 15 
Results (Aim 2) ................................................................................................................................................ 21 
To investigate pharmacologic modulation of O-GlcNAcylation for therapy of hyperammonemia ............. 21 
Discussion ........................................................................................................................................................ 33 
Methods ............................................................................................................................................................ 36 
Mouse studies ............................................................................................................................................... 36 
Helper-dependent adenoviral (HDAd) vectors ............................................................................................ 37 
Cell culture and transfection ....................................................................................................................... 38 
Immunoprecipitation ................................................................................................................................... 38 
Analyses of serum and plasma samples ....................................................................................................... 39 
UDP-GlcNAc analysis ................................................................................................................................. 39 
Western blot analysis ................................................................................................................................... 39 
Immunofluorescence.................................................................................................................................... 40 
RNA extraction and real-time PCR .............................................................................................................. 41 
Determination of 15N-labeled urea by nuclear magnetic resonance spectroscopy (NMR) ......................... 42 
Metabolite profiling of liver tissue by 1H-NMR .......................................................................................... 43 
NMR data processing and statistical analysis ............................................................................................ 43 
References ........................................................................................................................................................ 45 
2 
 
Abstract 
 
 
Ammonia is a toxic compound daily produced and consumed during cell metabolism 
in the body. It is converted to the less toxic substance urea by the urea cycle in the liver. 
Moreover, the urea cycle operates anatomically and functionally in sequence with the 
hepatic glutamine synthetase (GS) to detoxify ammonia and both systems are required 
for ammonia homeostasis. Urea cycle or GS deficiencies and liver diseases lead to 
defective ammonia removal causing hyperammonemia. Hyperammonemia is a life- 
threatening condition which may results in hepatic encephalopathy and death, if left 
untreated. Available therapies for hyperammonemia are partially effective and novel 
and improved therapies are required. Considering the cooperative role of GS in 
ammonia detoxification, gene therapy based on hepatic GS augmentation was 
investigated as a potential treatment against hyperammonemia. Thus, upregulation of 
hepatic GS protects wild-type mice against acute hyperammonemia. Notably, liver 
specific GS overexpression improved ammonia detoxification also in Cps1-deficient 
mice. As a result, hepatic GS augmentation therapy has potential for treatment of both 
primary and secondary forms of hyperammonemia. 
Furthermore ammonia can induce modification of O-GlcNAcylation levels. O- 
GlcNAcylation is a dynamic post-translational modification catalyzed by the enzyme 
O-GlcNAc transferase (OGT) whereas the O-GlcNAcase (OGA) removes O-GlcNAc. 
O-GlcNAcylation, once modulated, may be a new therapeutic target to treat 
hyperammonemia. Hence, the role of hepatic O-GlcNAcylation in ammonia 
detoxification was investigated. In vivo modulation of O-GlcNAcylation through both 
pharmacological (small molecules) and OGA knockdown approaches improved 
ammonia detoxification. Neither expression of genes encoding urea cycle enzymes nor 
protein levels  of these  enzymes were  affected  by OGA inhibition,  suggesting  that 
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hepatic O-GlcNAcylation regulates ammonia clearance capacity by enzymatic activity 
of the urea cycle. Finally, hepatic O-GlcNAcylation plays an important role in ammonia 
detoxification. Therefore OGA is a novel therapeutic target for treatment of 
hyperammonemia of both urea cycle disorders and acquired hyperammonemia. 
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ATP: adenosine triphosphate 
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carboxylase 
Vp: viral particles 
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Introduction 
 
 
 
Ammonia metabolism 
 
Nitrogen -the most abundant component of the earth atmosphere- is reduced to ammonia 
(NH3) by nitrogen-fixing bacteria before it can be utilized by humans [1]. Ammonia dissolved in water 
forms ammonium ions (NH4
+) and is assimilated into amino acids and other nitrogen-containing 
molecules. At physiological plasma and intracellular pH values, ammonia is present in its ionized 
form (ammonium, NH4+, pKa: 9.15). The concentration of ammonium in normal human plasma is 11-
50 µmol/L [1]. Free ammonium ions are continually produced and consumed during cell metabolism 
in the human body. Ammonia arises during the breakdown of nucleotides, polyamines and 
deamination of amino acids [2]. In addition, free ammonium ions are supplied by urease- producing 
urea-splitting bacteria in the gastrointestinal tract. The liver has a relevant role in maintaining normal 
ammonium metabolism through urea cycle and glutamine metabolism. In the liver both systems are 
required for ammonia detoxification [3], operating anatomically and functionally in sequence [4] (Fig. 
1). 
 
 
Figure  1.    Organization  of  hepatic  nitrogen  metabolism (metabolic  zonation).  Periportal  glutaminase is 
activated by ammonia and acts as ammonia amplifier. Its activity determines flux of ammonia through urea 
cycle, a low affinity system for ammonia detoxification. Glutamine synthetase in perivenous hepatocytes acts 
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as high affinity system for ammonia detoxification. Adapted from [3]. 
 
 
The urea cycle is a low-affinity and high capacity ammonia detoxification pathway occurring in 
periportal hepatocytes while glutamine synthetase (GS) in perivenous hepatocytes is a high-affinity 
ammonia scavenger system [3]. The urea cycle occurs only within the liver mitochondria and 
cytoplasm. The conversion from ammonia into urea involves five catalytic enzymes (carbamyl 
phosphate synthetase I, ornithine transcarbamylase, argininosuccinate synthase, argininosuccinate 
lyase, and arginase) and one enzyme that synthesizes an allosteric activator (N-acetylglutamate 
synthase) (Fig. 2). The initial steps of the urea cycle occurs in the mitochondria whereas the remaining 
three steps are cytosolic (Fig. 2). 
 
 
Figure 2. Schematic representation of urea cycle. The urea cycle is a metabolic pathway that converts highly 
toxic ammonia to urea which is nontoxic, highly soluble, and can rapidly be excreted by kidneys. Urea is formed 
from NH4+ (as derived from oxidative deamination of glutamate), HCO3-, the nitrogen of aspartate and ATP. 
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The conversion from ammonia to urea occurs through five reactions. The first and rate-limting step is needed 
for ammonia to enter the cycle in which ammonia is converted to carbamoyl phosphate. The following four 
enzymatic reactions are all a part of the cycle itself: one mitochondrial and three cytosolic. The synthesis of 
carbamoyl phosphate and the activity of urea cycle are dependent on the presence of N-acetylglutamic acid 
(NAG), which allosterically activates carbamoyl phosphate synthetase I (CPS1). The remaining enzymes of 
the cycle are controlled by the concentrations of their substrates. Adapted from [23]. 
 
 
GS, also known as glutamate-ammonia ligase enzyme (GLUL), is a cytosolic enzyme that 
incorporates an ammonia molecule into glutamate to form glutamine through an ATP-dependent 
reaction. It is highly conserved in living organisms and its expression and activity have been detected 
in several tissues including liver and brain (mostly astrocytes) [1]. Glutamine, the product of GS 
reaction, is the most abundant free amino acid in the human body and is crucial in essential pathways 
such as cell signaling, osmotic regulation, acid-base homeostasis and proliferation. Glutamine serves 
as a major nontoxic interorgan ammonia carrier [4]. 
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Hyperammonemia: pathogenesis and treatments 
 
Hyperammonemia is defined as a concentration of plasma ammonia level more than 50 µmol/L (> 
100 µmol/L in newborns). It can occur when ammonia detoxification is deficient (decreased urea 
cycle flux, insufficient activity of GS) or under conditions with increased ammonia production (drugs, 
infections, intestinal bacterial overgrowth or other catabolic states leading to endogenous protein 
degradation) [5]. Depending on the underlying pathophysiology, hyperammonemia can be defined as 
primary and secondary. Primary hyperammonemia is caused by inborn errors of metabolism, mainly 
urea cycle disorders (UCD) that may be due to deficiency of any of the enzymes in the urea cycle. 
UCD are all autosomal recessive except ornithine transcarbamylase (OTC) deficiency which is X- 
linked. Deficiency of Carbamoyl phosphate synthetase I (Cps1) is typically very severe because it is 
due to a defect in the initial incorporation of ammonia into intermediate compounds of urea cycle [6]. 
In contrast, secondary hyperammonemia is a result of accumulation of any of toxic metabolites or 
substrate deficiencies of the urea cycle [5]. The most common examples of secondary 
hyperammonemia include organic acidemias in which urea synthesis is impaired by reduced 
production of N-acetylglutamate (NAG), the allosteric activator of ureagenesis through carbamoyl 
phosphate synthetase I [1; 7; 8]. Interestingly, similar to inherited urea cycle disorders, patients with 
ultra-rare genetic GS deficiency also show hyperammonemia [9; 10]. Furthermore, GS expression and 
its activity is reduced in patients with liver cirrhosis and chronic hyperammonemia [11] and in mice 
liver-specific  deletion of GS results in hyperammonemia leading to neuronal and behavioural 
abnormalities [12]. As a result hyperammonemia occurs not only in UCD, congenital or acquired 
deficiency of any of the enzymes involved in the urea cycle disorders, but also in GS deficiency and 
in acute liver failure (sepsis and cirrhosis) [13]. Thus, also acquired impairment of the liver function 
leads to severe neurological disease. Consequently, an increase in the blood ammonia concentration 
leads to higher levels of ammonia in brain, eventually resulting in astrocyte swelling, increased blood-
brain barrier permeability, altered cerebral metabolism and neurotransmission and cerebral edema 
[14]. 
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Hyperammonemia can trigger hepatic encephalopathy (HE) a serious psychiatric and 
neurocognitive complication. 
 
Therapeutic approaches for hyperammonemia aim at reducing production by protein- 
restriction diet and uptake of ammonia (antibiotics, probiotics non-absorbable disaccharides) or 
improving endogenous detoxification systems (ammonia scavenger drugs, e.g. phenylacetate and 
phenylbutyrate) [14]. Despite these treatments, patients remain at risk of acute decompensation and 
liver transplantation is often considered [15; 16]. However, liver transplantation is hampered by risks 
of mortality and morbidity, largely related to long-term effects of immunosuppression. Therefore, 
there is a need for developing novel and more effective therapeutic strategies to reduce ammonia 
levels and to decrease mortality and morbidity in individuals with hyperammonemia [14]. 
11 
 
O-GlcNAcylation: mechanisms and functions 
 
O-GlcNAcylation (O-GlcNAc) is a post-translational modification (PTM) consisting of non- 
canonical glycosylation with the attachment of a O-linked N-acetylglucosamine (O-GlcNAc) to serine 
and threonine residues of cytoplasmic, nuclear and mitochondrial proteins [17]. Uridine diphosphate 
GlcNAc (UDP-GlcNAc) is the substrate of O-GlcNAc and it derives from the hexosamine 
biosynthetic pathway (HBP) which integrates glucose, amino acids, fatty acids and nucleotide 
metabolism to generate UDP-GlcNAc (Fig. 3). 
 
Figure 3. Dynamic, nutrient-sensitive O-GlcNAc cycling is modulated by metabolite and enzyme availability. 
Glucose, acetyl-CoA, ATP, glutamine, and uridine are required for synthesis of UDP-GlcNAc, the ultimate 
product of the hexosamine biosynthetic pathway (HBP). hOGT and hOGA splice variants are depicted. O- 
GlcNAc transferase (OGT) uses the nucleotide sugar to modify proteins, whereas O-GlcNAcase (OGA) 
catalyzes the removal of GlcNAc. Abbreviations: HAT: histone acetyltransferase; MTS, mitochondrial targeting 
sequence; PPO, phosphoinositide binding domain; TRP: tetratricopeptide repeats. Adapted from [22]. 
 
 
The attachment of the sugar is catalyzed by O-GlcNAc transferase (OGT) transferring a O-GlcNAc 
moiety from the donor substrate UDP-GlcNAc to the hydroxyl groups of serine 
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and threonine residues; whereas O-GlcNAcase (OGA) is responsible for the removal of the sugar 
modification. OGT and OGA are the only two enzymes involved in the regulation of this PTM. There 
are multiple isoforms of OGT and OGA. Based on splicing of amino-terminal tetratricopeptide repeats 
(TRPs), there are three isoforms of OGT: nucleocytoplasmic (ncOGT), mitochondrial (mOGT) and 
short (sOGT) that share common carboxy-terminal catalytic and phosphoinositide binding domains 
and differ for their subcellular localization. Moreover, OGA presents two isoforms: a 
nucleocytoplasmic isoform (ncOGA), which possesses both an N-terminal O-GlcNAc hydrolase 
domain and a C-terminal histone acetyltransferase-like domain (HAT-like) and a short isoform 
(sOGA), lacking HAT-like domains. O-GlcNAcylation interacts extensively with other PTMs 
especially with phosphorylation. O-GlcNAcylation occurs reciprocally or sequentially with 
phosphorylation on the same residues of several proteins [18;19] and it is thought that these two PTMs 
are in a dynamic equilibrium [20]. Like phosphorylation, O-GlcNAcylation is a dynamic modification 
and can be transferred to, and removed from, a protein many times during the lifespan of a protein 
[20]. While phosphorylation is controlled by a cascade of kinases and phosphatases, O- 
GlcNAcylation is regulated only by two enzymes, namely OGT and OGA. Similar to 
phosphorylation, O-GlcNAcylation strongly affects protein functions, such as catalytic activity or 
protein-protein interactions [21]. O-Glc-NAcylation targets include transcription factors and proteins 
involved in histone modifications, DNA methylation and intracellular signaling [22] (Fig. 4). 
Moreover, this PTM has been implicated in several metabolic pathways in liver such as carbohydrate 
and lipid metabolism, circadian clock, mitochondrial functions and autophagy [17]. Reversible 
protein O-GlcNAcylation was found to be induced by ammonia treatment in rat astrocytes suggesting 
that O-GlcNAcylation is involved in the pathophysiology of hepatic encephalopathy [21]. 
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Figure 4: Role of O-GlcNAcylation in human physiology and pathology states. The ubiquitous and essential 
modification of protein serine and threonine residues with O-GlcNAc modulates cell functions by responding 
to variable nutrient conditions. Aberrant O-GlcNAc modification is implicated in metabolic and 
neurodegenerative diseases, cancer, and autoimmune disorders. Abbreviations: OIP, OGT interacting protein. 
Adapted from [22]. 
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Aims of the thesis 
 
Hepatic GS augmentation and pharmacologic modulation of O-GlcNAcylation: new therapeutic 
approaches for hyperammonemia 
The goal of the thesis work was to investigate novel therapies for treatment of 
hyperammonemia by two independent studies. Recent findings suggested that enhancement of GS 
expression in muscle has therapeutic potential for treatment of hyperammonemia [15]. Moreover, 
increased activity of muscle GS induced by ornithine-phenylacetate treatment was found to reduce 
blood ammonia in rat models of chronic liver failure [13]. Based on these findings, I investigated the 
efficacy of hepatic GS overexpression for therapy of hyperammonemia. For a proof-of-concept study, 
I used an approach based on liver-directed gene transfer of GS (Aim 1). 
In aim 2 of this thesis, I investigated the relationship between O-GlcNAcylation and ammonia. 
Starting from the observation made in our laboratory that O-GlcNAcylation is an ammonia-induced 
PTM [21], I hypothesized that O-GlcNAcylation might be a novel therapeutic target for treatment of 
hyperammonemia. 
In summary, the main purpose of my thesis is to study novel and effective therapeutic approaches 
to treat hyperammonemia and towards this goal, I investigated : 
1.  the efficacy of hepatic GS supply in reducing hyperammonemia induced in acute and chronic 
models. 
2.  the efficacy of pharmacologic modulation of O-GlcNAcylation on improving ammonia 
detoxification capacity. 
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Results 
 
AIM 1: Hepatic GS overexpression for therapy of hyperammonemia 
 
To investigate the potential of hepatic GS augmentation as a therapeutic approach for 
hyperammonemia, a helper dependent adenoviral vector (HDAd) expressing the murine glutamine 
synthetase under the control of a liver-specific expression cassette (HDAd-GS) was generated (Fig. 
5A). HDAd can efficiently deliver genes to hepatocytes to provide long-term, high-level transgene 
expression without inducing chronic toxicity [25] and have been used in a variety of inherited liver 
diseases [27;29;30]. It has long been appreciated that hepatocyte gene therapy using HDAd, the latest 
generation of recombinant vectors, mediates high level transgene expression with negligible chronic 
toxicity, as shown by several studies in small and large animal models [24;25; 26; 27; 28]. The helper 
dependent adenoviral vector was produced to express murine glutamine synthetase under the control 
of the liver-specific promoter of phosphoenolpyruvate carboxykinase (PEPCK). Firstly, C57BL/6 
wild-type mice were injected with HDAd-GS or HDAd-AFP encoding the unrelated nontoxic, non 
immunogenic alpha-fetoprotein (AFP) reporter gene under the control of the same liver-specific 
expression cassette. Compared to C57BL/6 wild-type control mice injected with HDAd-AFP, 
increased hepatic GS protein expression levels was observed in C57BL/6 wild-type injected with the 
vector expressing GS by western blot (Fig. 5B). 
 
 
 
 
 
Figure 5. (A) A helper-dependent adenoviral vector was produced to express murine GS under 
the control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter. The vector also contains inverted 
terminal repeat (ITR), a packaging signal (Ψ), the ApoA1 intron (ApoA1in), the hepatic locus control region (LCR), 
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a growth hormone polyadenylation signal (GHpA) and woodchuck hepatitis post-transcriptional regulatory element 
(WPRE). (B) Western blot of GS in livers of HDAd- GS-injected C57BL/6 wild-type mice compared to controls 
injected with a vector expressing an unrelated reporter gene (HDAd-AFP) at 12 weeks post vector injection. 
Ornithine aminotransferase (OAT) and p115 were used as loading controls. Band densitometric densities of HDAd-
AFP: 1.00 ± 0.05 AU [arbitrary unit] vs HDAd-GS: 1.88 ± 0.20 AU; P = 0.022, two-tailed unpaired Student's t test; 
n = 3/group. 
 
 
These wild-type mice injected with HDAd-GS or HDAd-AFP were treated intraperitoneally with 
ammonium chloride (NH4Cl) at the dose of 10 mmol/kg. Serum ammonia levels did not change at 
baseline but mice with hepatic GS upregulation showed a 39% reduction in serum ammonia at 0.5 
hours after i.p. ammonium chloride challenge compared to controls (P < 0.05; Fig. 6A). A 
concomitant increase in serum levels of glutamine (the product of the GS reaction) occurred in mice 
with hepatic GS overexpression compared to HDAd-AFP-injected controls (Fig. 6B), whereas serum 
urea was unaffected (Fig. 6C). 
 
 
 
 
 
Figure 6. Upregulation of hepatic GS protects wild-type mice against acute hyperammonemia. (A-C) Serum 
ammonia, glutamine, and urea at baseline and 0.5 hours after intraperitoneal injections of ammonium chloride 
(10 mmol/kg) in wild-type mice injected with HDAd-GS or HDAd-AFP vector. (n ≥ 9/group). *P < 0.05; **P < 
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0.01. Abbreviations: AFP: α-fetoprotein; GS: glutamine synthetase; HDAd: helper-dependent adenoviral 
vector; Pi: post injection. 
 
 
These results suggested that liver-specific GS overexpression improved ammonia detoxification 
through an increase in hepatic glutamine synthesis in wild-type mice with acute hyperammonemia. 
To investigate whether increased hepatic GS expression is effective for therapy of 
hyperammonemia due to UCD, mice with deficiency of CPS1 were next injected with HDAd-GS or 
HDAd-AFP. CPS1 is the initial and rate-limiting step of urea cycle that forms carbamoyl phosphate 
from bicarbonate, ammonia and ATP. Bi-allelic mutations of Cps1 result in a UCD presenting with 
hyperammonemia, often with reduced citrulline and without orotic aciduria. CPS1 deficiency is a 
particularly challenging disorder because it lacks early recognition signs and typically results in early 
neonatal death. Moreover, therapeutic interventions have limited efficacy and most patients develop 
long-term neurologic sequelae. 
These experiments were performed in collaboration with Dr. Gerald S. Lipshutz (UCLA, Los 
Angeles, California, USA) using Cre-mediated conditional hepatic deficient mouse for Cps1 
generated in his laboratory to overcome the early lethality of mice deficient in CPS1 enzyme [31]. 
Deletion of the Cps1 locus was achieved in adult transgenic Cps1tm1c/tm1c mice by i.v. injection of a 
low dose of serotype 8 adeno-associated viral vector (AAV8) expressing the Cre recombinase inducing 
non lethal increase in plasma ammonia [32]. This conditional murine model recapitulates the clinical 
and biochemical phenotype of human patients with CPS1 deficiency. As a result, Cre- mediated 
reduction in hepatic Cps1 mRNA levels was similar in mice injected with HDAd expressing either 
AFP or GS (Fig. 7). 
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Figure 7. Expression of Cps1 gene in HDAd-GS and HDAd-AFP injected mice. Cps1 mRNA expression in 
Cre-mediated Cps1-deficient (Cps1-def) mice injected with HDAd-GS or HDAd-AFP compared to control wild- 
type animals (n = 5/group). **p< 0.01 (One-way ANOVA). Abbreviations: AFP: α-fetoprotein; GS: glutamine 
synthetase; HDAd: helper-dependent adenoviral vector; ns: not significant. 
 
Similar reduction of CPS1 levels in mice expressing either AFP or GS when compared to wild-type mice 
was shown by immunofluorescence performed on livers with anti-CPS1 antibody (Fig. 8A). Moreover, 
mice expressing either AFP or GS showed decreased blood urea nitrogen (BUN) compared to wild- 
type controls that was also similar among the two groups (Fig. 8B), confirming the urea cycle 
deficiency affecting Cps1-def mice. 
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Figure 8. (A) Representative images of immunofluorescence microscopy for CPS1 (red) in livers harvested at 
day 28 post-vector administration in Cps1-def mice injected with HDAd-GS or HDAd-AFP compared to control 
wild-type animals. (B) BUN in plasma harvested at day 28 post vector administration in Cre-mediated Cps1- 
deficient (Cps1-def) mice injected with HDAd-GS or HDAd-AFP compared to control wild-type animals 
(n = 5/group). *P < 0.05 (one-way ANOVA). Data represent averages ± SEM. Abbreviations: AFP: α- 
fetoprotein; BUN: blood urea nitrogen; CPS1: carbamoyl phosphate synthetase 1. GS: glutamine synthetase; 
HDAd: helper-dependent adenoviral vector; ns: not significant. 
 
 
As expected, livers of HDAd-GS-injected Cps1tm1c/tm1c mice showed increased GS expression compared to 
HDAd-AFP controls (P < 0.01; Fig. 9A). Interestingly, mice treated with HDAd-GS showed an increased 
plasma glutamine/ammonia ratio (Fig. 9B), suggesting that increased glutamine synthesis is responsible for 
the reduced blood ammonia levels induced by HDAd-GS. 
 
 
 
Figure 9. Expression of GS in livers of HDAd-GS- and HDAd-AFP-injected mice. (A) Glul mRNA levels of livers 
of Cps1-deficient (Cps1-def) mice injected with HDAd-GS or HDAd-AFP and harvested at day 28. 
**P < 0.01 (n = 5/group). (B) Plasma glutamine/ammonia ratio at day 28 in Cps1-def mice injected with HDAd- 
GS or HDAd-AFP. *P < 0.05 (n = 5/group). Abbreviations: AFP: α-fetoprotein; GS: glutamine synthetase; 
HDAd: helper-dependent adenoviral vector. 
 
 
Cps1-deficient mice injected with HDAd-GS showed reduced serum ammonia at baseline and after i.p. 
challenge with ammonium chloride compared to Cps1-deficient mice injected with HDAd-AFP (Fig. 10). 
Notably, baseline plasma ammonia levels were reduced  to  wild-type levels in Cps1-deficient mice injected 
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with HDAd-GS. Reduction of ammonia levels was also detected at 20 and 60 minutes post-ammonia challenge 
although these levels were higher than wild-type mice. 
 
 
 
 
Figure 10. Liver-specific GS overexpression improved ammonia detoxification in Cps1-deficient mice. Plasma 
ammonia in Cps1-deficient (Cps1-def) mice injected with HDAd-GS (n = 9) or HDAd-AFP vector (n = 10) at 
baseline, 20 and 60 minutes after intraperitoneal injections of ammonium chloride (5 mmol/kg). #P = 0.055; 
*P < 0.05; **P < 0.01 (two-way ANOVA). Control ammonia-treated wild-type mice are also included (n = 5). Data 
represent averages ± SEM. Abbreviations: AFP, α-fetoprotein; GS, glutamine synthetase; HDAd, helper- 
dependent adenoviral vector; Pi, post injection. 
 
 
Taken together, these results support the therapeutic potential of hepatic GS augmentation for 
treatment of acute hyperammonemia in an inherited ammonia detoxification disorder. Of note, these results 
were recently published in the journal J Inherit Metab Dis and I was included as co-author of this study [33]. 
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AIM 2: To investigate pharmacologic modulation of O-GlcNAcylation for therapy of 
hyperammonemia 
The first evidence that links O-GlcNAcylation to ammonia came from cultured rat astrocytes 
in which ammonia increases levels of O-GlcNAcylated proteins in a time and dose dependent manner 
[21]. To investigate the relationship between ammonia and O-GlcNAcylation, hepatic O- 
GlcNAcylation levels were analyzed under acute hyperammonemia condition (NH4Cl:10 mmol/Kg 
i.p.) in C57BL/6 wild-type mice. An increase of hepatic O-GlcNAcylation occurred in response to 
ammonia challenge (Fig. 11A,B). Notably, UDP-GlcNAc levels increased in ammonia treated mice 
compared to the vehicle treated mice (Fig. 11C). Next, I investigated the involvement of hepatic O- 
GlcNAcylation in ammonia detoxification. 
 
 
 
. 
 
Figure 11. Acute hyperammonemia activates O-GlcNAcylation in liver. (A-B) Western blot of O-GlcNAcylated 
proteins of total lysates of liver of wild-type mice at baseline and 60 minutes after i.p. injection of ammonia load 
(NH4Cl: 10 mmol/kg i.p. for 60 min). GAPDH was used as loading control. RL2 and CRD110 antibody were 
used to detec O-GlcNAcylated proteins. GAPDH was used as loading control. C) Hepatic UDP-GlcNAc levels 
harvested 60 minutes after injection of saline (control) or NH4Cl. P < 0.021565378 (n=5/group). 
 
To this end, C57BL/6 wild-type mice were injected with PUGNAc (7 mg/kg, i.p.) or Thiamet- 
G (40 mg/kg, i.p.) to increase liver O-GlcNAcylated proteins. Both PUGNAc and Thiamet-G are two 
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established and commercially available OGA inhibitors [34; 35]. Given its high selectivity for human 
OGA over other glycosidases and functionally related b-N-acetylglucosaminidases both in vitro and 
in vivo, Thiamet-G is accepted as a powerful tool for probing the functional role of O-GlcNAc [20; 
36]. As expected, 48 h after treatments with either drug, O-GlcNAc protein levels were increased 
compared to vehicle-treated controls (Fig. 12A). Next, mice were treated with ammonia (NH4Cl: 10 
mmol/kg, i.p.) to induce acute hyperammonemia [37; 38]. Vehicle treated animals showed an increase 
of circulating ammonia at 0.5 h post-NH4Cl challenge whereas lower serum ammonia levels were 
detected in mice treated with PUGNAc (Fig. 12B, orange bars) or Thiamet-G (Fig. 12B, blue bars). 
 
 
 
Figure 12. Increased O-GlcNAcylation reduces blood ammonia levels. (A) Western blot of hepatic O-GlcNac 
protein levels in hyperammonemic mice treated with OGA inhibitors: Thiamtet-G (40 mg/kg, i.p.) and PUGNAc 
(7 mg/kg, i.p.). GAPDH was used as loading control. (B) Serum ammonia levels at baseline and 60 min after 
i.p. of NH 4 Cl in mice pre-treated with PUGNAc or Thiamet-G compared to vehicle-treated controls. Data are 
expressed as means ± SEM. *p < 0.05; n ≥ 7. Abbreviations: TMG: Thiamet-G; Pi: post-injection. 
 
Next, we evaluated ureagenesis by 15N-NMR spectroscopy in PUGNAc and Thiamet G, as previously 
reported [37]. Interestingly, both PUGNAc and Thiamet-G mice showed an increased serum levels of 
15N-labeled urea (Figure 13), indicating increased ureagenesis. Liver content of glutamine instead 
was not affected by neither vehicle nor PUGNAc (Fig. 14). In summary, PUGNAc and Thiamet-G 
treatments improved ammonia detoxification capacity by increasing ureagenesis. 
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Figure 13. Hepatic O-GlcNAcylation increases ureagenesis. Serum levels of 15N-labeled urea at 0.5 h after 
 
i.p. injection of 15NH4Cl in vehicle and OGA-inhibitors-treated mice. Data are expressed as means ± SEM. 
 
**P < 0.01; n ≥4/group. Abbreviations: pi: post-injection. 
 
 
 
 
 
 
 
 
 
 
Figure 14. Hepatic O-GlcNAcylation does not affect glutamine levels. Glutamine levels in livers of mice 
treated with vehicle or PUGNAc. P < 0.088 (n ≥ 5/group). Abbreviation: Gln: glutamine. 
 
 
 
 
Moreover, these results suggest that pharmacological enhancement of O-GlcNAcylation has potential 
for therapy of acute hyperammonemia. To confirm the role of OGA as a target for therapy of 
hyperammonemia, we performed in vivo knock-down of OGA that was confirmed by western blot 
(Fig. 15) . 
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Figure 15. Western blot for OGT and OGA from livers of wild-type mice treated with specific siRNA against 
OGT and OGA (1 mg/kg, single injection, i.v.) harvested 6 days after siRNA administration. Control group 
received a commercial scrambled siRNA. β-actin was used as loading control. Abbreviations: ns: not 
significant. 
 
 
As expected, an acute ammonia load increased hepatic O-GlcNAcylated protein levels 
compared to untreated animals but the increase in O-GlcNAcylation proteins was potentiated in mice 
with knock-down of OGA (Fig. 16). 
25 
 
 
 
Figure 16. O-GlcNAc protein levels in livers from 
mice with OGA knock-down during acute 
hyperammonemia. β-actin was used as loading 
control. 
 
 
 
 
 
 
 
 
 
 
 
Liver knock-down of OGA resulted in significantly lower ammonia levels compared to siRNA 
treated controls (Fig. 17). 
 
 
 
 
 
Figure 17. Serum ammonia at baseline, 30 and 60 
min after i.p. injection of NH4Cl in mice with OGA 
knock-down. *P < 0.05 (n ≥ 5/group). 
Abbreviations: pi: post-injection; ns: not significant. 
 
 
 
 
 
 
The decreased ammonia was associated with enhanced ureagenesis in mice with siRNA- 
mediated hepatic knockdown of OGA (Fig. 18), as shown by by 15N-NMR spectroscopy. 
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Figure 18. Serum levels of 15N-labeled urea at 30 min after i.p. injection of 15NH4Cl in mice with OGA knock- 
down compared to controls. *P < 0.05 (n ≥ 5/group). Abbreviations: pi: post-injection. 
 
 
Taken together, these results indicate that OGA is a drug target for treatment of hyperammonemia. 
 
To investigate the mechanism underlying the protection against hyperammonemia induced by 
increased O-GlcNAcylation, I first evaluated gene expression of the urea cycle genes and other 
relevant genes encoding enzymes involved in ammonia detoxification by qPCR in mice treated with 
PUGNAc or Thiamet-G. As shown in Fig. 19 expression of the evaluated genes was unaffected by 
OGA inhibition, neither their protein levels analyzed by western blot (Fig. 20). 
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Figure 19. Gene expression of urea cycle enzymes were not affected by OGA pharmacologic inhibition. 
Relative expression levels of Nags, Cps1, Otc, Ass1, Asl, Arg1, Glud, Glul, and Oat mRNA in livers from mice 
treated with PUGNAc (7 mg/Kg i.p.) (A) and Thiamet-G (40 mg/Kg i.p.) (B), or vehicle. *p < 0.05 (n ≥ 4/group). 
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Figure 20. ARG1, GS, OAT, CPS1 and OTC protein expression was unaffected in livers of mice treated with 
OGA inhibitors. Western blot analysis of urea cycle proteins of total liver lysates of mice treated with PUGNAc 
(7 mg/Kg i.p.) and Thiamet-G (40 mg/Kg i.p.) or vehicle and their relative densiometric quantifications. β-actin 
and GAPDH were used as loading control. 
 
 
 
Protein levels of CPS1, the initial and rate-limiting step of ureagenesis, were also unaffected 
by OGA inhibition. CPS1 is a mitochondrial enzyme (molecular weight 116 KDa) that synthesizes 
carbamoyl phosphate from bicarbonate and ammonia via three separate reactions: phosphorylation of 
hydrogen carbonate to carboxy-phosphate (using one ATP molecule); a nucleophilic attack of 
ammonia on carboxyphosphate yielding carbamate; and phosphorylation of carbamate forming 
carbamoyl phosphate (another ATP molecule consumed) (Fig. 21). CPS1 requires the allosteric 
activator N-acetyl-L-glutamate. Interestingly, CPS1 has been previously found to be O- 
GlcNAcylated in three different domains: two of them are responsible for bicarbonate and carbamate 
phosphorylation; while the third O-GlcNAcylated domain is an integrating structural domain [39; 40; 
41; 42]. Nevertheless, the functional consequence of CPS1 O-GlcNAcylation is unclear. 
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Figure 21. Scheme of the mature CPS1 protein with its two moieties (top). The middle bar indicates the two 
sequence-related halves of the large moiety. Domain composition with names and boundaries, given as 
residue numbers, is indicated in the lower bar. The three steps of the CPS1 reaction are shown below the 
corresponding domains where they occur. The blue arrow indicates carbamate migration between the 
phosphorylation active centers, a process contributed mainly by residues from both phosphorylation domains. 
Adapted from [43]. 
O-GlcNAcylation increases enzymatic activity of glucose-6-phosphate dehydrogenase (G6PD), the 
rate-limiting enzyme of the pentose phosphate pathway (PPP) [44] and I investigated whether CPS1 
O-GlcNAcylation is increased by OGA inhibition both in vitro and in vivo. Hela cells were treated 
with PUGNAc or Thiamet-G to increase protein O-GlcNAcylation (Fig. 22A). The same total cell 
lysates were immunoprecipitated with anti-CPS1 antibody or a control IgG. Immunoblotting assay 
showed that endogenous CPS1 was O-GlcNAcylated and O-GlcNAcylation increased upon OGA 
inhibition by PUGNAc or Thiamet-G compared to vehicle treated cells (Fig. 22A). Murine CPS1 was 
also transfected in HEK293 cells and in HuH7 cells that were also treated with PUGNAc or Thiamet- 
G (Fig. 22B-C). Western blot of total lysates confirmed increased O-GlcNAcylation of CPS1 in 
PUGNAc or Thiamet-G treated HEK293 and HuH7 cells. 
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Figure 22. (A) HeLa cells were treated for 24 h with PUGNAc (100 µM) or Thiamet-G (10 µM). As expected, 
elevated O-GlcNAcylated proteins were detected in whole cell lysates (WCL-Input) whereas total amount of 
CPS1 was unaffected. Increased O-GlcNAcylation of CPS1 was in immunoprecipated CPS1. (B) HEK293 and 
(C) HuH7 cells were transfected with a plasmid encoding CPS1 for 48 hours and treated with PUGNAc (100 
 
µM) or Thiamet-G (10 µM) for 24 hrs. Western blot of WCL and an IP are shown. Abbreviations: IP: 
immunoprecipitation; PG: PUGNAc; TMG: Thiamet-G; WCL: whole cell lysate. 
 
Next, I investigated in vivo CPS1 O-GlcNAcylation in liver lysates of mice treated with OGA 
inhibitors by immunoprecipitation with an anti-CPS1antibody. CPS1 was confirmed to be O– 
GlcNAcylated that was increased by Thiamet-G (Fig. 23). 
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Figure 23. Wild-type mice were treated with Thiamet-G (40 mg/Kg) for two days i.p. or vehicle before proteins 
were isolated and subjected to direct immunoprecipitation with anti-CPS1 antibody. Western bot of input of 
total lysates is shown in the same panel. β-actin was used as loading control. IgG was used as negative control 
for IP experiments. Abbreviations: IP: immunoprecipitation; TL: total lysate; TMG: Thiamet-G. 
 
 
Based on these results, I hypothesize that increased O-GlcNAcylation of CPS1 results in increased 
enzyme activity and ureagenesis. To confirm this hypothesis, kinetic studies to evaluate changes in 
substrate affinity (Km) and/or catalytic efficiency (kcat/Km) are currently ongoing in the laboratory 
of our collaborator, Johannes Haberle. 
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Discussion 
 
Ammonia is a toxic compound daily generated in our organism that needs to be efficiently eliminated. 
The liver plays a major role in ammonia detoxification accomplished by the urea cycle in periportal 
hepatocytes and GS in the perivenous compartment. Notably, these two systems operate anatomically 
and functionally in sequence in the liver (metabolic zonation) [3]. The ureagenesis is a high-affinity 
system for ammonia detoxification in which CPS1 is the starter of the urea cycle and catalyzes the 
condensation of bicarbonate and ammonia to form carbamoylphosphate inside the mitochondrial 
matrix. The urea cycle is a sequence of six enzymatic and two transport steps needed to metabolize 
and excrete the nitrogen generated by the breakdown of amino acids in protein and other nitrogen- 
containing molecules. In contrast, the cytosolic GS is a cytosolic enzyme that catalyzes ATP- 
dependent production of glutamine from glutamate and ammonia. When the detoxification system 
fails or there is an increased production of ammonia, toxic ammonia accumulates within the body 
causing hyperammonemia [5]. Hyperammonemia can be classified into primary and secondary 
hyperammonemia and leads to encephalopathy which can manifest as cerebral edema, vomiting, 
blurred vision, asterixis, and seizures. It can also cause coma and irreversible brain damage if not 
treated early and thoroughly [5]. Treatments against hyperammonemia are insufficient and more 
effective therapy are needed. The aim of the present thesis work is to study new and effective therapies 
for the treatment of hyperammonemia investigating both hepatic GS augmentation and modulation of 
O- GlcNAcylation. For GS augmentation, we used a helper dependent adenoviral vector to deliver the 
murine GS to hepatocytes. Notably, increased levels of hepatic GS provided an amelioration of 
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detoxification, protecting wild-type mice against acute hyperammonemia. Moreover, the same vector 
was used also to deliver GS to Cps1 deficient mice resulting in reduction of plasma ammonia levels. 
In summary, in two different models of hyperammonemia (primary and secondary) we showed that 
GS augmentation is effective for therapy of hyperammonemia. In addition, treatments aiming at 
increasing GS activity can be combined with available treatments such as low protein diet, ammonia 
scavengers, or the recently described activation of hepatic autophagy [37] to obtain more effective 
control of blood ammonia levels. Interestingly, improved ammonia control can be obtained by 
supplementation with glutamate (or its precursors) or phenylacetate to enhance ammonia removal by 
increased synthesis and clearance of glutamine, respectively [45]. Hepatic GS upregulation might also 
be achieved by systemic mRNA delivery, a therapeutic strategy that has been successfully used for 
correction on an inborn error of metabolism [46]. Moreover, GS augmentation therapy might be 
achieved by uploading of GS onto lipid‐ or polymeric‐based nanoparticles [47] for systemic delivery 
or with membrane derived from natural cells such as erythrocytes or white blood cells [48]. In 
addition, ammonia detoxification may be further improved by vesicles uploaded with recombinant 
GS enzyme through liposome‐supported peritoneal dialysis [49]. Small molecule drugs upregulating 
hepatic GS expression are another attractive approach. Interestingly, glucocorticoids are known to 
positively regulate expression of GS at the transcriptional level in multiple tissues [50]. 
Dexamethasone was indeed found to be effective in mice at increasing ammonia detoxification [48]. 
However, overexpression of GS in astrocytes is likely to be detrimental because it could lower the 
threshold of brain toxicity since cerebral edema depends on glutamine synthesis in astrocytes [51]. 
Hence, treatments with low glucocorticoid doses or other drugs upregulating GS in livers but not in 
astrocytes are desirable. Current guidelines for management of patients with suspected or confirmed 
diagnosis of urea cycle disorders recommend avoidance of steroids because they induce protein 
catabolism and can trigger hyperammonemia [52]. This recommendation is based on anecdotal 
experience in patients with acute decompensation following steroid treatments [53]. The results of 
our study suggest that GS upregulation is protective against hyperammonemia although the increased 
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GS expression in astrocytes is likely to be detrimental. 
 
Furthermore, I investigated the correlation between ammonia and O-GlcNAcylation. O-
GlcNAcylation (O-GlcNAc) is a post-translational modification (PTM) consisting of non-canonical 
glycosylation with the attachment of O-linked N-acetylglucosamine (O-GlcNAc) to serine and 
threonine residues of proteins [22]. Reversible protein O-GlcNAcylation was found to be induced by 
ammonia treatment in rat astrocytes suggesting that O-GlcNAcylation is involved in the 
pathophysiology of hepatic encephalopathy [21]. Hence, the role of hepatic O-GlcNAcylation in 
ammonia detoxification was investigated. Towards this goal, I examined the efficacy of 
pharmacologic modulation of O-GlcNAcylation on improving ammonia detoxification capacity. In 
vivo modulation of O-GlcNAcylation through OGA inhibitors and OGA knockdown approaches 
improved ammonia detoxification. Therefore, OGA is a promising therapeutic target for therapy of 
acute hyperammonemia. Moreover, I investigated the mechanism underlying the protection against 
hyperammonemia induced by increased O-GlcNAcylation. Neither gene nor protein expression levels 
of urea cycle enzymes were increased by OGA inhibition, suggesting that hepatic O-GlcNAcylation 
regulates ammonia clearance capacity by affecting enzymatic activity of the urea cycle.  In particular, 
I focused my attention on carbamoyl phosphate synthetase I (CPS1), the initial and rate-limiting step 
of ureagenesis. This enzyme has been previously found to be O- GlcNAcylated in three different 
domains [39; 40; 41; 42] with unknown functional consequences. I confirmed that CPS1 is O-
GlcNAcylated and that its level of O-GlcNAcylation is increased upon OGA inhibition by two 
independent methods. Based on these results, I hypothesized that increased O-GlcNAcylation of 
CPS1 results in increased enzyme activity and ureagenesis. However, further studies are needed to 
show whether CPS1 with increased O- GlcNAcylation has higher catalytic activity. 
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Materials and Methods 
 
Mouse studies. Male wild-type (WT) 6-week-old C57BL/6 (Charles River Laboratories, Calco, Italy) 
and adult female transgenic Cps1tm1c/tm1cmice [32] were randomly assigned to treatment groups. 
Investigators were not blinded to allocation during experiments and outcome assessment. All 
intravenous (i.v.) injections were performed by retro-orbital injections under isoflurane anesthesia. 
Vectors were prepared in sterile pharmaceutical-grade saline. Male and female mice were equally 
represented throughout the study. WT and Cps1tm1c/tm1cmice were injected with a dose of 1 × 1013 viral 
particles (vp)/kg of helper-dependent adenoviral (HDAd)-GS or HDAd-alpha-fetoprotein (AFP) (α-
fetoprotein) as a control [32]. The ammonium intraperitoneal (i.p.) challenge in WT mice was 
performed at 4 weeks post vector injection. Mice were overnight fasted before i.p. injections of 10 
mmol/kg of ammonium chloride (Merck, Darmstadt, Germany) dissolved in water [37]. Three days 
after the injections of HDAd expressing either AFP or GS, Cps1tm1c/tm1cmice were injected with 1.5 
× 1010genome copies (gc)/mouse of AAV8 vector expressing Cre recombinase under the control of 
the thyroxine binding globulin promoter (liver-specific) [33]. Cps1tm1c/tm1cmice were weighed daily 
and monitored for any signs of poor health. In Cps1tm1c/tm1cmice, the i.p. ammonia challenge was also 
performed 4 weeks after the injections of the HDAd vectors but with a lower dose of i.p. 5 mmol/kg 
ammonium chloride and without prior fasting. Male wild-type 6-week-old C57BL/6 (Charles River 
Laboratories, Calco, Italy) were injected i.p. with Thiamet-G (Sigma-Aldrich; 40 mg/kg, for two days 
before i.p. injections of 10 mmol/kg of ammonium chloride) and PUGNAc (Sigma-Aldrich; 7 mg/kg, 
for two days before the ammonia i.p. injections). Both drugs were dissolved in PBS. Male WT 6- 
week-old C57BL/6 (Charles River Laboratories, Calco, Italy) were depleted of OGT or OGA in the 
liver by using the Invivofectamine 3.0 reagent system (Cat#: IVF3001; ThermoFisher, Milan S.R.L.). 
The commercially available siRNA duplex solution was prepared and diluted according to the 
manufacturer’s instructions. Preparation of the final injection solution was performed following the 
established Thermofisher protocol. Briefly, the same day of administration corresponding pre- 
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designed siRNA (ThermoFisher) were mixed with the complexation buffer and then the 
Invivofectamine® 3.0 reagent. The solution was vortexed, incubated at 50°C for 30 min and finally 
diluted in sterile PBS. Intravenous (i.v.) administration was performed by retro-orbital injection of 
200 µl of solution at a final concentration of 1 mg/kg. No adverse side effects were observed after 
injection. Control mice received the Silencer™ Select Negative Control No.1 siRNA (Cat#: 4390843, 
ThermoFisher, Milan S.R.L.). To induce hepatic knock-down of OGT, mice received a mix of pre- 
designed siRNA to deplete murine OGT (ID: #173150 and #173151; Cat#AM16708, ThermoFisher, 
Milan S.R.L.). Similarly, to induce knock-down of OGA in liver, mice received a mix of pre-designed 
siRNA against mouse OGA (MGEA5 gene) (ID: #167691 and #167693; Cat#: AM16708, 
ThermoFisher, Milan S.R.L). The knockdown was left for 6 days and then animals were subjected to 
an acute ammonia load. Livers were harvested and specific knock-down efficacy was evaluated by 
western blot analysis. Blood samples were collected by retro-orbital bleedings at the indicated time 
points. Mice were sacrificed by cervical dislocation or isoflurane overdose. Serum or plasma and liver 
samples were harvested and stored at -80° C until analyses. Mouse procedures were performed in 
accordance with regulations and were authorized by both the Italian Ministry of Health and the 
Institutional Animal Care and Use Committee (IACUC) of David Geffen School of Medicine at 
UCLA, Los Angeles, United States. 
 
 
Helper-dependent adenoviral (HDAd) vectors. HDAd-GS and HDAd-AFP vectors both bear a liver- 
specific expression cassette driving the expression of either mouse GS or baboon alpha-fetoprotein 
(AFP), respectively [28]. HDAd vectors were produced as previously reported [54] in 116 cells 
regularly tested and found negative for Mycoplasma by quantitative real time polymerase chain 
reaction PCR. Mouse GS cDNA and mouse Cps1 cDNA were synthesized by Life Technologies 
(Carlsbad, CA) [32]. 
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Cell culture and transfection. HeLa and Hek293 cells were cultured in Dulbecco’s modified Eagle’s 
medium and 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in 5% CO2. Cells were 
transfected with the PEPCK-WL-CPS1 plasmid using LipoD293™ DNA transfection reagent (Cat# 
Sl 100668; Ver.II, Tebu Bio S.R.L, Milan) according to manufacturer’s instructions. After 24 h of 
transfection, Thiamet-G (10 µM) or PUGNAc (100 µM) were added to the medium; both were 
dissolved in PBS. PEPCK-WL-CPS1 plasmid bears the expression cassette including the liver- 
specific promoter of phosphoenolpyruvate carboxykinase (PEPCK) and other regulatory elements 
like the woodchuck hepatitis virus post regulatory element (WPRE), the Locus Control Region (LCR) 
from the apoE locus, the bovine growth hormone polyadenylation signal as described elsewhere [27; 
28]. 
 
 
Immunoprecipitation (IP). For immunoprecipitation, cells and liver samples were lysed in cold RIPA 
lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.1% SDS 
and 1mM Thiamet G) in the presence of protease inhibitors (Sigma-Aldrich). The lysates were 
incubated on ice for 20 minutes with gentle swirling and centrifuged at 13 200 rpm for 10 minutes to 
pellet nuclei and cell debris. The supernatants were collected and subjected to protein quantification 
using the Bradford Reagent (Bio-Rad, Hercules, California, USA). 300 µg of each lysate was then 
incubated with 3 µl of antibody anti-CPS1 antibody (Cat# ab45956;Abcam, Cambridge, UK) ( 100µg 
proteins:1 µl antibody ratio) or anti rabbit IgG isotope as negative control (Cat# 31235 Thermo Fisher 
Scientific-0.4 ug/ul) and subjected to immunoprecipitation at 4°C overnight. The day after each 
immunoprecipitate was incubated with magnetic beads Dynabeads™ Protein G (Cat# 1004 D Thermo 
Fisher Scientific) for 2 hours at 4 °C. Immunoprecipitaton binded with the beads Dynabeads™ Protein 
G is separated from flow through with DynaMag™ magnet (Cat# 12321D Thermo Fisher Scientific) 
that is optimized for efficient magnetic separation of Dynabeads® due to the unique magnetic 
properties of Dynabeads, according to the manifacture’s protocol. Then 
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immunoprecipitation-Dynabeads™ Protein G complex was washed thrice with PBS containing 
0.02% Tween-20 before precipitated proteins were eluted through DynaMag™ magnet using 2× 
Laemmli sample buffer (1v/v ). Finally, IP samples were put at 100 ° C for 5 minutes and analyzed 
by SDS–PAGE in a 7.5% gel. 
Analyses of serum and plasma samples. Serum or plasma ammonia levels were measured by an 
ammonia colorimetric assay kit (Cat# K370-100; BioVision Incorporated, Milpitas, California, USA 
or Cat# ab83360; Abcam, Cambridge,UK), respectively. Serum or plasma glutamine concentrations 
were measured by a colorimetric assay kit (Cat#K556-100; BioVision Incorporated, Milpitas, 
California, USA). Serum urea content was determined by an assay kit based on Jung's method (Cat# 
K376-100; BioVision Incor-porated, Milpitas, California, USA). For blood urea nitrogen (BUN), 
10μL of plasma per sample were pipetted into cups and placed into a Vet Excel Clinical Chemistry 
Analyzer (Alfa Wassermann Diagnostic Technologies, West Caldwell, New Jersey, USA). 
Calculation of urea nitrogen concentration was performed automatically by the clinical chemistry 
system. Hepatic ATP determination was performed by a fluorometric assay kit according to the 
manufacturer'sinstructions (Cat# K354-100; BioVision Incorporated, Mil-pitas, California, USA). 
Liver lysates were homogenized in the corresponding hydrolysis buffer using a Tissue Lyser LT 
(Qiagen, Venlo, Netherlands). Hepatic ATP levels were normalized for protein concentrations 
determined by Bradford Reagent (Bio-Rad, Hercules, California, USA). 
 
 
UDP-GlcNAc analysis. Hepatic level of UDP-GlcNAc was determined by hydrophilic interaction 
liquid chromatography (HILIC) at the Academic Medical Center (Amsterdam, the Netherlands). 
 
 
Western blot analysis.  Liver specimens and cell samples were homogenized in  RIPA buffer in the 
presence of complete protease inhibitor cocktail (Sigma-Aldrich,St. Louis, Missouri, USA), 
incubated for 20 minutes at 4° C and centrifuged at 13 200 rpm for 10 minutes. Pellets were discarded 
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and supernatants were used for western blots. Total protein concentration in cellular extracts was 
measured using the Bradford Reagent (Bio-Rad, Hercules, California, USA). Protein extracts were 
separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto hydrophobic polyvinylidene fluoride membranes (Immobilon-P PVDF Membrane, 
Merck). Blots were blocked with trisbuffered saline (TBS)-Tween-20 containing 5% nonfat milk for 
1 hour at room temperature followed by incubation with primary antibody overnight at 4°C. Primary 
antibodies were: rabbit anti-Glutamine Synthetase (GS) (Cat# b16802; Abcam, Cambridge, UK), 
mouse anti-O-GlcNAcylation RL2 ( Cat # Ab2739; Abcam, Cambridge, UK) and mouse anti-O- 
GlcNAcylation CTD110.6 ( Cat # 9875; Cell Signaling), mouse anti- Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Cat# sc-32233; Santa Cruz Biotechnology), rabbit anti-Ornithine Amino 
Transferase (OAT) (Cat# ab137679; Abcam, Cambridge, UK), mouse anti-Beta actin (ACTB) (Cat# 
NB600-501;Novus Biological), rabbit anti-Arginase(ARG1) ( Cat# ab91279;Abcam, Cambridge, 
UK), rabbit anti-Carbamoyl phosphate synthetase 1 (CPS1) (Cat# ab45956;Abcam, Cambridge, UK) 
and rabbit anti-Ornithine Carbamoyl Transferase(OTC) (Cat# NBP1-31582, Novusbio), anti rabbit 
anti-p115 [54], mouse anti-O-GlcNAcTransferase (OGT) (Cat# ab184198;Abcam, Cambridge). 
Proteins of interest were detected with horseradish peroxidase-conjugated goat anti-rabbit or anti- 
mouse IgG antibody (GE Healthcare, Chicago, Illinois, USA). Peroxidase substrate was provided by 
enhanced chemiluminescence (ECL) Western Blotting Substrate kit (Pierce, Waltham, Massachusetts, 
USA). Densitometric analyses of the western blotting bands were performed using Image J Software 
(National Institutes of Health, Bethesda, Maryland, USA). 
 
 
Immunofluorescence. Immunofluorescence was performed as previously described [32]. Liver 
sections were fixed in 10% neutral buffered formalin, stored in 70% ethanol and embedded in paraffin 
blocks followed by cutting the sections at 4-μm thickness. Sections were then deparaffinized in xylene 
and rehydrated in serial ethanol washes. Antigen retrieval was performed in 10-mM sodium citrate 
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buffer pH 6.0, after which the sections were permeabilized in 0.1% Triton X-100 and blocked with 
10% normal goatserum. Slides were incubated with anti-carbamoyl phosphatesynthetase 1 (CPS1) 
antibody (Cat# ab45956; Abcam, Cam-bridge, UK) and anti-GLUL antibody (Cat# ab64613; Abcam, 
Cambridge, UK), both at 1μg/mL in the blocking buffer overnight at 4°C. Secondary antibody staining 
was performed at room temperature for 1 hour using Alexa Fluor594 goat anti-rabbit (A- 11012; 
Invitrogen, San Diego, Cali-fornia, USA) and Alexa Fluor 488 goat antimouse (A-11001; Invitrogen, 
San Diego, California, USA) antibodies. Cell nuclei were counterstained with 4',6- diamidino-2-phe-
nylindole (DAPI) using VECTASHIELD Antifade Mount-ing Medium. Visualization of the stained 
sections was performed using Olympus IX71 Fluorescence Microscope. 
 
 
RNA extraction and real-time PCR 
 
RNA extraction and real-time PCR were performed as previously descrived [33]. Liver pieces were 
homogenized, and RNA was extracted by column purification (Cat# 11828665001; Roche 
Mannheim, Germany). Purified RNA was used to generate cDNA (Cat#04379012001; Roche 
Mannheim, Germany) for qPCR with BioRad SYBR Green (Cat# 1725270; Bio-Rad, Hercules, 
California, USA), and IQ2 iCycler. β-actin gene was used as endogenous control. Fold changes were 
calculated using the delta-delta-Ct (DDCt) method. Cps1 primers were: forward 
CACCAATTTCCAGGTGACCA; reverse TACTGCTT-TAGGCGGCCTTT; Glul primers were: 
forward CCACTT-GAACAAAGGCATCA; reverse GTCCTTCTCCGGTACCATCA; Actb primers 
were: forward CTAAGGCCAACCGT-GAAAAG; reverse ACCAGAGGCATACAGGGACA. 
Total RNA from livers was extracted using the RNeasy mini kit (Qiagen). RNA was retrotranscribed 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative PCRs 
were set up using SYBR Green Master Mix and run in duplicate on a Light Cycler 480 system (Roche). 
The running program was as follows: preheating, 5 minutes at 95 °C: 40 cycles of 15 seconds 
at 95 °C, 15 seconds at 60 °C, and 25 seconds at 72 °C. Mouse β2-microglobulin (B2m) was used as 
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housekeeping genes. Data were analyzed using LightCycler 480 software, version 1.5 (Roche). 
Primers used are reported previously [55] and were: 
Arg1: forward CATTGGCTTGCGAGACGTAGAC; reverse GCTGAAGGTCTCTTCCATCACC 
 
Asl; forward CTGCAGGGAAGCTACACACA; reverse CGGAGAGTTTTGAGCAGGTC 
Ass1: forward AACATTGGCCAGAAGGAAGA; reverse CCACAAATTCCTTGCTCACA 
Cps1: forward CATCCGCCTGCTAGTTAAGC; reverse CCCAGCAATCAAAAGTCCAT 
Gls2: forward CAGGAGCGTATCCCTATCCA; reverse CTGCATCTTGCTCATGCAGT 
GluD1: forward GTCAGCGATCCAGGACATCT; reverse CTATGGAGCTGGCCAAGAAG 
Glul: forward CCACTTGAACAAAGGCATCA; reverse GTCCTTCTCCGGTACCATCA 
Nags: forward ACCTGTTGCAGTGGTGTCTG; reverse GTCACCTCCAGCGAGTCAAG 
Oat: forward TGTAGCCCTGGAGAGAGGA; reverse CTTGGCTGACAGCACCATAA 
Otc: forward GGATAGGGGATGGGAACAAT; reverse TCTGGCTCATAACCCTTTGG 
 
 
 
 
Determination of 15N-labeled urea by nuclear magnetic resonance spectroscopy (NMR). C57BL/6 
wild-type mice were injected i.p. with Thiamet-G or PUGNAc or OGT and OGA siRNA or vehicle 
prior to the i.p. injection of 10 mmol/kg of 15N-labeled ammonium chloride (98% enriched in 15N, 
Sigma). Blood samples were collected by retro-orbital bleedings at 0, 30 and 60 min post-injection. 
The amount of 15N-labeled urea in sera was evaluated by comparison to 15N-leucine signal added to 
all samples as an internal reference as previously described [37]. Biological 15N-labeled urea in each 
sample was quantified from the observed 15N peak intensities (in integrated areas) compared to the 
internal standard. One-dimensional (1D) 15N spectra were recorded at 44.55 MHz on a Bruker 
AVANCE™III HD-400 spectrometer, equipped with a BBO BB-H&F-D CryoProbe™ Prodigy fitted 
with a gradient along the Z-axis, at a probe temperature of 27°C (300 K). The pulse Ineptrd sequence 
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(INEPT for non-selective polarization transfer with decoupling during acquisition) was used with the 
following parameters: d1 = 5 s, J = 9 0Hz, ns = 15000 and acquisition time of 0.809 s. The leucine 
signal was assumed to resonate at 18.00 ppm, and therefore the urea signal resonated at 55.80 ppm. 
 
Metabolite profiling of liver tissue by 1H-NMR. Tissues were mechanically disrupted to extract the 
metabolites of interest (lipids, carbohydrates, amino acids, and other small metabolites) while leaving 
other compounds (DNA, RNA, and proteins) in the tissue pellet. Homogenization of 200 mg of frozen 
tissue samples was carried out in 8 ml/g of wet tissue made of methanol and 1.70 ml/g per wet tissue 
of water (all solvents were cold) with UltraTurrax for 2 min on ice. 4 ml/g wet tissue of chloroform 
were added and the homogenate was gently stirred and mixed on ice for 10 min (the solution must be 
mono-phasic). Then, additional 4 ml/g wet tissue of chloroform and 4 ml/g wet tissue of water were 
added and the final mixture was well shaken and centrifuged at 12,000 g for 15 min at 4°C. This 
procedure separates three phases: water/methanol on the top (aqueous phase with the polar 
metabolites), denatured proteins and cellular debris in the middle, and chloroform at the bottom (lipid 
phase with lipophilic compounds). The upper and the lower layers were transferred into glass vials, 
the solvents removed under a stream of dry nitrogen, and stored at -80°C until the analyses [37]. 
 
NMR data processing and statistical analysis. The spectral 0.50–9.40 ppm region of the high- 
resolution 1H-NMR spectra was automatically data reduced to integrated regions (buckets) of 0.04- 
ppm each using the AMIX 3.6 package (Bruker Biospin, Germany). The residual water resonance 
region (4.72–5.10 ppm) was excluded, and the integrated region was normalized to the total spectrum 
area. To differentiate liver tissues through NMR spectra, we carried out a multivariate statistical data 
analysis using projection methods. The integrated data reduced format of the spectra was imported 
into SIMCA-P+ 15 package (Umetrics, Umea, Sweden) [37]. 
 
Statistical analyses. Data are expressed as means ±SEM. A two-tailed unpaired Student's t-test was 
performed when comparing two groups of mice. One-way ANOVA and Tukey's post-hoc tests were 
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performed when comparing more than two groups relative to a single factor. Two-way ANOVA and 
Tukey's post-hoc tests or Sidak's multiple tests were performed when comparing two groups relative 
to two factors. No statistical methods were used to predetermine the sample size. A P-value < 0.05 
was considered statistically significant [33]. 
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